Table 1.
Association between HOXD-AS1 Expression and the Clinicopathological Features of TCGA Prostate Cancer Patients, n = 374
| Characteristics | Cases, n (%) | χ2 | p Value | |
|---|---|---|---|---|
| HOXD-AS1 expression | Low | High | ||
| Age, year (n = 368) | 0.596 | 0.44 | ||
| ≤60 | 58 (16) | 105 (29) | ||
| >60 | 81 (22) | 124 (33) | ||
| Gleason score (n = 374) | 7.285 | 0.007a | ||
| 6–7 (3+4) | 76 (20) | 91 (24) | ||
| 7 (4+3)–10 | 66 (18) | 141 (38) | ||
| Tumor stage (n = 368) | 6.367 | 0.013a | ||
| T2 | 72 (20) | 89 (24) | ||
| T3-4 | 66 (18) | 141 (38) | ||
| Lymph nodes status (n = 316) | 4.419 | 0.036a | ||
| Negative | 102 (32) | 168 (54) | ||
| Positive | 10 (3) | 36 (11) | ||
a
p < 0.05 was considered significant. Patients with no available clinical data were excluded from analysis with respect to the comparison of HOXD-AS1 expression.